期刊
MOLECULES
卷 20, 期 2, 页码 2728-2769出版社
MDPI
DOI: 10.3390/molecules20022728
关键词
-
资金
- NUHS Bench-to- Bedside-To-Product grant
- Singapore Ministry of Education [MOE2012-T2-2-139]
- NUHS Bench-to-Bedside-To-Product [R-184-000-243-515]
- Cancer Science Institute of Singapore, Experimental Therapeutics I Program [R-713-001-011-271]
Despite significant advances in treatment modalities over the last decade, neither the incidence of the disease nor the mortality due to cancer has altered in the last thirty years. Available anti-cancer drugs exhibit limited efficacy, associated with severe side effects, and are also expensive. Thus identification of pharmacological agents that do not have these disadvantages is required. Curcumin, a polyphenolic compound derived from turmeric (Curcumin longa), is one such agent that has been extensively studied over the last three to four decades for its potential anti-inflammatory and/or anti-cancer effects. Curcumin has been found to suppress initiation, progression, and metastasis of a variety of tumors. These anti-cancer effects are predominantly mediated through its negative regulation of various transcription factors, growth factors, inflammatory cytokines, protein kinases, and other oncogenic molecules. It also abrogates proliferation of cancer cells by arresting them at different phases of the cell cycle and/or by inducing their apoptosis. The current review focuses on the diverse molecular targets modulated by curcumin that contribute to its efficacy against various human cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据